Literature DB >> 24600143

Can hormone replacement therapy prior to oocyte donation cycle in women with premature ovarian failure improve pregnancy rate?

Nikita Naredi1, K Sandeep1, V D S Jamwal2.   

Abstract

BACKGROUND: Infertility is an important issue in women with Premature Ovarian Failure (POF). With no conclusive treatment available to enhance fertility in these women, it is the use of donor eggs with In-Vitro Fertilization (IVF) which can fulfil their desire to become a mother in a novel way. Hormone replacement therapy (HRT) in POF apart from correcting the endocrine defect also helps in improving the milieu of the uterus by improving its vascularisation and the sub endometrial blood flow. We thus aimed to carry out a study to find out whether hormone replacement therapy if administered prior to the oocyte donation cycle in patients of premature ovarian failure improves the pregnancy rate.
METHODS: A comparative study was carried out incorporating 46 subjects with 23 in each group. Group A received HRT prior to their oocyte donation cycle while the second group entered into the oocyte donation programme directly after an artificially induced menstruation.
RESULTS: It was observed that, although the HRT group had a slightly higher pregnancy rate, with a better mean endometrial thickness as compared to the non HRT group it was not statistically significant.
CONCLUSIONS: Institution of hormone replacement therapy does improve the vascularisation of the uterus, corrects the histologic features of the uterine lining and makes the endometrium receptive but whether it enhances the pregnancy rate needs to be elucidated with further studies.

Entities:  

Keywords:  Hormone replacement therapy; Oocyte donation; Premature ovarian failure

Year:  2013        PMID: 24600143      PMCID: PMC3862755          DOI: 10.1016/j.mjafi.2013.06.011

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  9 in total

Review 1.  Premature ovarian failure from current perspective.

Authors:  Arif Kokcu
Journal:  Gynecol Endocrinol       Date:  2010-08       Impact factor: 2.260

2.  Bone loss in young women with karyotypically normal spontaneous premature ovarian failure.

Authors:  J N Anasti; S N Kalantaridou; L M Kimzey; R A Defensor; L M Nelson
Journal:  Obstet Gynecol       Date:  1998-01       Impact factor: 7.661

3.  Premature gonadal failure.

Authors:  C B Coulam
Journal:  Fertil Steril       Date:  1982-12       Impact factor: 7.329

Review 4.  Premature ovarian failure.

Authors:  Deepti Goswami; Gerard S Conway
Journal:  Hum Reprod Update       Date:  2005-05-26       Impact factor: 15.610

Review 5.  Spontaneous premature ovarian failure: management challenges.

Authors:  Emmanuel Kalu; Nick Panay
Journal:  Gynecol Endocrinol       Date:  2008-05       Impact factor: 2.260

Review 6.  New advances in the treatment of infertility in women with ovarian failure.

Authors:  R S Morris; M V Sauer
Journal:  Curr Opin Obstet Gynecol       Date:  1993-06       Impact factor: 1.927

7.  The variation of endometrial response to a standard hormone replacement therapy in women with premature ovarian failure. An ultrasonographic and histological study.

Authors:  T C Li; P Dockery; S S Ramsewak; L Klentzeris; E A Lenton; I D Cooke
Journal:  Br J Obstet Gynaecol       Date:  1991-07

8.  Endometrial blood flow response to hormone replacement therapy in women with premature ovarian failure: a transvaginal Doppler study.

Authors:  R Achiron; D Levran; E Sivan; S Lipitz; J Dor; S Mashiach
Journal:  Fertil Steril       Date:  1995-03       Impact factor: 7.329

9.  Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure who are resistant to hormone replacement therapy.

Authors:  Hélène Letur-Konirsch; Sylvie Delanian
Journal:  Fertil Steril       Date:  2003-02       Impact factor: 7.329

  9 in total
  1 in total

Review 1.  Premature ovarian insufficiency: the context of long-term effects.

Authors:  A Podfigurna-Stopa; A Czyzyk; M Grymowicz; R Smolarczyk; K Katulski; K Czajkowski; B Meczekalski
Journal:  J Endocrinol Invest       Date:  2016-04-18       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.